Onco Actu du 31 août 2015

	1. Biologie
A fuller picture of cancer [Harvard Gazette] “This migration ability helps to explain how driver mutations are able to dominate a tumor, and also explains why targeted therapies fail within a few months as resistance evolves,” Nowak said. “So what we have is a mathematical model for solid tumors, and it’s this local migration that explains these questions.”
	3.1 Tabac
What Should Public Health Officials Be Doing About E-Cigarettes? [Health Affairs Blog] This delay leaves some to wonder: why didn’t Big Tobacco champion e-cigarettes much earlier if they truly believed them to be “harm reduction” devices? In the following blog post, I suggest five key steps that policymakers, regulators, and public health advocates should take on e-cigarettes.
Public Health England under fire for saying e-cigarettes are 95% safer [The Guardian] Editorial in Lancet medical journal criticises PHE for basing its advice on research funded by organisations with links to the tobacco industry
	4. Dépistage, diagnostic et pronostic
Overdiagnosis of Cancer Conference [National Cancer Institute] Although there may be a perception that overdiagnosis is limited to some prevalent cancers like prostate and breast cancer, Dr. Kramer said that’s not the case.
	4.9 Dép., diag. & prono. - Sein
Poll Finds Most Women Believe Mammograms Should Be Done Annually [NPR] The finding is at odds with current recommendations by the U.S. Preventive Services Task Force that women with typical risks for breast cancer have screening mammograms every two years starting at age 50 and until they turn 75.
	5. Traitements
Chemo drug works by tricking cells into thinking they're infected [Cancer Research UK] The discovery suggests that the treatment, called a 'hypomethylating' drug, could have wider uses. It could also lead to new combinations of existing therapies, and even the development of completely new drugs, the researchers say.
	5.2 Pharma
In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer [Xconomy] Importantly, Tavazoie notes, activating APOE, RGX-104 spurs on the innate immune system to fight cancer. That’s the body’s first line of defense, and an arm of the immune system that the “checkpoint inhibitor” cancer drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo)—which have started to completely change cancer care—don’t impact.
	5.2.1 Pharma - Partenariats
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies [BMS] QIMR Berghofer Medical Research Institute is a world leading translational research institute focused on cancer, infectious diseases, mental health and a range of complex disorders.
	6. Lutte contre les cancers
How we’re building a community to beat oesophageal cancer [Cancer Research UK] The aim of the conference, held earlier this month, was to bring together the world’s leading oesophageal cancer experts for the first time. And by getting everyone in one room, our hope was to invigorate research ideas and stimulate progress in understanding and treating the disease.
In cancer treatment, precision medicine is less precise than promised [The Boston Globe] Setbacks like Moore’s show that genetic profiling of tumors is, at this point, no more a cure for every cancer than angiogenesis inhibitors, which cut off a tumor’s blood supply, or other much-hyped treatments have been.
	6.7 DMP, Big Data & applis
NHS approves electronic consent technology in clinical trials [Pharmafile] Clinical technology and services company Mytrus has announced that its software platform for electronic informed consent has received approval for use by Britain's National Health Service (NHS); the first time e-Consent technology will be used in a trial in England.